ASH earnings analysis
What we found in ASH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ashland reported Q2 2026 revenue of $482 million, a slight increase of 1% year-over-year, while EPS was reported at $0.34, missing estimates of $0.95. The company continues to face operational challenges but achieved positive cash flow from operations. Management anticipates ongoing adjustments in response to geopolitical factors and market conditions.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Slightly Up YoY
- Q2 2026 revenue was $482 million, up 1% from $479 million in Q2 2025.
- EPS Lower than Expectations
- Diluted EPS for Q2 2026 was $0.34, below the estimate of $0.95.
- Positive Free Cash Flow
- Free cash flow stood at $95 million for Q2 2026, showing solid cash generation despite operational challenges.
- Cost Reduction Initiatives
- Restructuring actions resulted in $10 million savings, indicating ongoing efforts to enhance operational efficiency.
- Improved SG&A Expense
- Selling, general, and administrative expenses decreased by $6 million to $79 million, benefiting from restructuring actions.
- Segment Resilience
- Life Sciences segment remains strong, contributing 36% to total sales, consistent with prior year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operational Challenges Persist
- Continued issues with soft pricing and startup delays at Calvert City affecting profitability.
- Geopolitical Risks
- Uncertainties from ongoing geopolitical conflicts (e.g., Ukraine/Russia) present risks to supply chains and market stability.
- Tariffs and Trade Policies
- Ongoing risks related to tariffs could strain supply chains and increase operational costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.34
- Gross margin
- 30.5%
- Operating margin
- 8.1%
- Segment
- Life Sciences
- Segment
- Personal Care
- Segment
- Specialty Additives
- Segment
- Intermediates
What they said about what is next.
Updated full-year revenue guidance reflects slower-than-expected ramp-up at Hopewell.
The filing reads about the same as the one before it.
What came before.
- 10-Q · February 3, 2026
- Ashland reported quarterly sales of $386 million, down $19 million (‑4.7%) year-over-year and down $91 million versus the prior quarter. GAAP net loss narrowed to $12 million (loss of $0.26 per share) from a $165…
- 10-K · November 20, 2025
- Ashland positions itself as a global additives and specialty ingredients company focused on sustainability and differentiated chemistries across four reportable segments (Life Sciences, Personal Care, Specialty…
- 10-Q · July 30, 2025
- Ashland reported a $463 million quarter (down $81 million vs. prior year) with a $742 million net loss driven by a $706 million non‑cash goodwill impairment. Adjusted EBITDA remained positive at $113 million but…
- 10-Q · May 1, 2025
- Ashland reported quarter sales of $479 million (down $96 million vs. prior-year quarter of $575 million) with diluted net income per share of $0.65. Gross margin expanded to 30.7% from 28.0% and operating income…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ASH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever